PATIENT-FOCUSED.

SCIENCE-DRIVEN.

We are committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.

Approach mob

ROR1 cell-surface protein is expressed on many hematologic and solid tumors but is absent from normal tissues, making it an attractive tumor-specific therapeutic target. Emerging preliminary data from an ongoing Phase 1 clinical trial validate the potential for ROR1-mediated anti-tumor activity.

Led by industry veterans, VelosBio has developed its first ADC linking a humanized anti-ROR1 monoclonal antibody to the cytotoxin, monomethyl auristatin E (MMAE). This lead investigational drug, VLS-101, has demonstrated positive preclinical results in tumor models and currently is being evaluated in a Phase 1, first-in-human, dose-escalation and cohort-expansion study in patients with hematologic malignancies.

Applying its proprietary ROR1-targeting technology, VelosBio is generating additional ADC and BiAb therapies with the potential to offer clinical benefit across a range of hematologic and solid tumors.

Therapeutic Target Triangle Copy

Now Leaving The VelosBio Site.

Disclaimer Close Button SVG

Disclaimer: The information you have requested is not provided by VelosBio Inc. (“VelosBio”) but by a third party and should not be construed as representing the views of VelosBio. VelosBio does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom.

Continue Offsite